The perspective of the site as a silent partner

Monday, August 24, 2015

The Pulse on Site Success by Jeffrey Adelglass

If it has not become apparent to you over the last few years that the landscape is changing regarding the importance of a perspective site’s offer to sponsors and CROs, then one might infer you are missing the opportunity to better position your site for recognition and success.

[Read More]

Janus, Roche collaborate in autoimmune diseases

Friday, August 21, 2015

Janus Biotherapeutics, a Massachusetts-based autoimmunity therapeutics company, is collaborating with Roche on the development of a small molecule toll-like receptor (TLR) inhibitor with the potential to address several autoimmune diseases. TLRs are class of proteins in the innate immune system. Evidence links aberrant TLR activation and signaling with the development of autoimmune disorders. Janus will work exclusively with Roche on TLR R&D.

[Read More]

Roche to acquire Kapa Biosystems

Thursday, August 20, 2015

Roche has signed a definitive agreement to acquire Kapa Biosystems, a privately held company based in Wilmington, Mass. Kapa Biosystems is a provider of genomic tools in the life sciences sector that employs proprietary technologies to optimize enzymes for next-generation sequencing (NGS), as well as polymerase chain reaction (PCR) and real-time PCR applications.

[Read More]

Roche app measures Parkinson’s disease fluctuations

Monday, August 17, 2015

Roche Pharma Research & Early Development (pRED) has developed a smartphone-based monitoring system for those with Parkinson’s disease (PD) that complements the traditional physician-led assessments with automated tests that continuously measure their symptom fluctuations. It could be the first time that such an app has been used to measure disease and symptom severity in a medicine development program in PD.

[Read More]

Roche acquires GeneWEAVE

Thursday, August 13, 2015

Roche has signed a definitive agreement to acquire GeneWEAVE BioSciences, a Los Gatos, Calif.-based, privately held company focused on clinical microbiology diagnostics solutions. Roche will pay GeneWEAVE shareholders $190 million upfront and up to $235 million in contingent product related milestones. The transaction is subject to customary closing conditions and, once closed, GeneWEAVE will be integrated into Roche Molecular Diagnostics.

[Read More]

Tekmira changes name to Arbutus Biopharma, a hepatitis B solutions company

Wednesday, July 22, 2015

Tekmira Pharmaceuticals, headquartered in Vancouver, Canada, plans to change its corporate name to Arbutus Biopharma, a therapeutic solutions company focused on developing a cure for chronic hepatitis B virus infection (HBV), to be effective on or before Aug. 3. The name change affirms the successful integration of OnCore BioPharma and Tekmira Pharmaceuticals into a combined company with the singular goal of delivering a cure for chronic HBV. The combined entity currently fields a large portfolio of HBV product candidates in the industry.

[Read More]